The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study

Bibliographic Details
Title: The prognostic impact of Her2 status in early triple negative breast cancer: a Turkish Oncology Group (TOG) study
Authors: Neslihan Özyurt, Ali Alkan, Burcu Gülbağcı, Mustafa Seyyar, Esra Aşık, Mustafa Şahbazlar, Mehmet Türker, Oğuzcan Kınıkoğlu, Tahir Yerlikaya, Gülhan Dinç, Ali Aytaç, Ziya Kalkan, Senar Ebinç, İlkay Gültürk, Merve Keskinkılıç, Zehra Sucuoğlu İşleyen, Dilek Çağlayan, Alper Türkel, Esra Aydın, Teoman Şakalar, Serhat Sekmek, Nilgün Yıldırım, Sinem Koçak, Kerem Okutur, Ahmet Özveren, Bengü Dursun, Sait Kitaplı, Orhan Önder Eren, İsmail Beypınar, İlhan Hacıbekiroğlu, Devrim Çabuk, Elanur Karaman, Ömer Acar, Semra Paydaş, Melek Karakurt Eryılmaz, Bilgin Demir, Zeynep Oruç, Mesut Yılmaz, Fatih Selçuk Biricik, Derya Kıvrak Salim, Özgür Tanrıverdi, Mutlu Doğan
Source: Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Publisher Information: Nature Portfolio, 2024.
Publication Year: 2024
Collection: LCC:Medicine
LCC:Science
Subject Terms: Medicine, Science
More Details: Abstract The studies evaluating the impact of Her2 levels in neoadjuvant setting have conflicting data. The aim of the study was to evaluate the prognostic impact of Her2 status in early triple negative breast cancer(TNBC). In the study TNBC patients who were treated with neoadjuvant chemotherapy (NAC) and surgery were analyzed retrospectively. The primary aim of the study was to analyze the impact of Her2 status(Her2-0 and Her2-low) on pathological complete response (pCR). The secondary objectives were disease free survival (DFS) and overall survival (OS). 620 female triple negative breast cancer patients were evaluated. 427 patients (68.9%) had Her2-0 and 193(31.1%) had her2-low pathology. The pCR rates were similar between Her2-0 and Her2-low patients (33.0% vs. 27.5%, p = 0.098). Although Her2-0 group has better DFS (106 vs. 50 months, p = 0.002), in multivariate analysis it had a HR of 0.74 (p = 0.06). In addition, OS was similar (131 vs. 105 months, p = 0.13) with a HR of 0.88 (p = 0.61). In multivariate analysis; presence of LVI (HR:2.2 (95% CI 1.1–3.5) p = 0.001), Clinical stage T1/T2 (HR:0.39 (95% CI 0.2–0.6) p
Document Type: article
File Description: electronic resource
Language: English
ISSN: 2045-2322
Relation: https://doaj.org/toc/2045-2322
DOI: 10.1038/s41598-024-75293-5
Access URL: https://doaj.org/article/ce3cface4e834236bebf941d34a5f4df
Accession Number: edsdoj.3cface4e834236bebf941d34a5f4df
Database: Directory of Open Access Journals
Full text is not displayed to guests.
More Details
ISSN:20452322
DOI:10.1038/s41598-024-75293-5
Published in:Scientific Reports
Language:English